Bioventus Management
Management criteria checks 2/4
Bioventus' CEO is Rob Claypoole, appointed in Jan 2024, has a tenure of 2.17 years. total yearly compensation is $6.38M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $1.04M. The average tenure of the management team and the board of directors is 2.9 years and 5.1 years respectively.
Key information
Rob Claypoole
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 12.23% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.9yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
Bioventus: A New Start
Dec 02Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly
Nov 26
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative
Aug 14Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 09
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
May 07Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Mar 08Bioventus: Amply Rewarded For Recent Progress
Jan 05Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Aug 12Bioventus: Bullish On Path To Profitability
Jan 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$23m |
| Sep 27 2025 | n/a | n/a | US$10m |
| Jun 28 2025 | n/a | n/a | US$2m |
| Mar 29 2025 | n/a | n/a | -US$31m |
| Dec 31 2024 | US$6m | US$780k | -US$36m |
Compensation vs Market: Rob's total compensation ($USD6.38M) is above average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Insufficient data to compare Rob's compensation with company performance.
CEO
Rob Claypoole (52 yo)
Mr. Robert E. Claypoole, also known as Rob, is President, Chief Executive Officer and Director of Bioventus Inc. from January 10, 2024. He was Executive Vice President and President, US for Mlnlycke Health...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.2yrs | US$6.38m | 0.17% $ 1.0m | |
| Senior VP & CFO | 4yrs | US$2.09m | 0.23% $ 1.4m | |
| Senior VP | 8.6yrs | US$1.63m | 0.20% $ 1.2m | |
| Senior Vice President of Operations | 2.4yrs | no data | no data | |
| Vice President of Investor Relations & Treasurer | no data | no data | no data | |
| Senior VP & Chief Compliance Officer | 5.6yrs | no data | 0.086% $ 514.4k | |
| Senior VP & Chief Human Resources Officer | 2.9yrs | no data | no data | |
| Senior VP & GM of Surgical | 1.3yrs | no data | no data |
Experienced Management: BVS's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.2yrs | US$6.38m | 0.17% $ 1.0m | |
| Independent Director | 5.5yrs | US$234.00k | 0.17% $ 1.0m | |
| Independent Director | 3.2yrs | US$248.00k | 0.12% $ 708.6k | |
| Independent Director | 5.5yrs | US$173.00k | 0.13% $ 758.6k | |
| Independent Chairman of the Board | 5.5yrs | US$288.00k | 0.38% $ 2.3m | |
| Independent Director | 5.5yrs | US$235.70k | 0.13% $ 758.6k | |
| Independent Director | 5.5yrs | US$253.00k | 0.16% $ 943.0k | |
| Independent Director | 4.7yrs | US$247.50k | 0.12% $ 702.9k | |
| Independent Director | 5.5yrs | no data | 0.017% $ 104.1k | |
| Independent Director | 4.4yrs | US$238.00k | 0.11% $ 680.3k | |
| Independent Director | 4.2yrs | US$238.00k | 0.085% $ 507.3k | |
| Director | less than a year | no data | no data |
Experienced Board: BVS's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 21:47 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bioventus Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Kyle Rose | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |